Metastatic Non-small Cell Lung Cancer Epidemiology Forecast 2026-2035

Metastatic non-small cell lung cancer (NSCLC) represents the advanced stage of the most prevalent lung cancer subtype worldwide. Lung cancer remains the leading cause of cancer deaths globally, and NSCLC accounts for approximately 85% of all lung cancers. Additionally, as per global estimates, lung cancer caused nearly 1.8 million deaths worldwide in 2022. According to metastatic non-small cell lung cancer epidemiology forecast, the disease burden remains substantial due to high late-stage diagnosis rates.

Metastatic Non-small Cell Lung Cancer Epidemiology Forecast Report Coverage

The analyst's “Metastatic Non-small Cell Lung Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of metastatic non-small cell lung cancer. It projects the future incidence and prevalence rates of metastatic non-small cell lung cancer cases across various populations. The study covers age, gender, and type as major determinants of the metastatic non-small cell lung cancer population. The report highlights patterns in the prevalence of metastatic non-small cell lung cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of metastatic non-small cell lung cancer in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Metastatic Non-small Cell Lung Cancer Understanding: Disease Overview

Metastatic non-small cell lung cancer (NSCLC) refers to an advanced stage of lung cancer in which malignant cells originating in lung tissues spread to distant organs such as the brain, liver, bones, or adrenal glands. It typically develops from genetic mutations in lung epithelial cells, often associated with risk factors including tobacco smoking, environmental pollutants, and occupational carcinogens. NSCLC accounts for most lung cancer cases and includes several histological subtypes, primarily adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Metastasis occurs through lymphatic or hematogenous dissemination, significantly complicating disease management and prognosis.

Metastatic Non-small Cell Lung Cancer Epidemiology Perspective

The metastatic non-small cell lung cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the metastatic non-small cell lung cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for metastatic non-small cell lung cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Feiyang Li et al., 2025, non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer cases, and a substantial proportion of patients are diagnosed at advanced stages. Among elderly patients, 50-60% present with advanced disease, reflecting a considerable burden of metastatic NSCLC worldwide.
• As per Sarah Waliany et al., 2024, the 5-year survival rate for all NSCLC cases is about 25%, whereas patients with metastatic non-small cell lung cancer (mNSCLC) have a markedly lower 5-year survival rate of approximately 7%, demonstrating the severe prognosis of metastatic disease.
• According to Feiyang Li et al., 2025, around half of NSCLC patients are diagnosed at age 70 years or older, and older individuals frequently present with advanced or metastatic stages, emphasizing the strong age-related epidemiological burden of metastatic NSCLC.
• As per Gregory J. Riely et al., 2024, in the United States in 2024, about 234,580 new lung and bronchial cancer cases are projected, including 116,310 males and 118,270 females, indicating a relatively balanced gender distribution among patients with lung cancer, including those at risk of developing metastatic NSCLC.
• According to Gregory J. Riely et al., 2024, approximately 125,070 deaths from lung and bronchial cancer are expected in the United States in 2024, highlighting the high mortality burden associated with advanced and metastatic forms of lung cancer, particularly metastatic NSCLC.

Country-wise Metastatic Non-small Cell Lung Cancer Epidemiology

The metastatic non-small cell lung cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiological burden of metastatic non-small cell lung cancer (NSCLC) varies across major global regions, reflecting differences in lung cancer incidence and diagnosis patterns. According to David E. Midthun, 2024, lung cancer affected approximately 2.2 million individuals worldwide in 2020 and caused about 1.8 million deaths, while the United States reports nearly 235,000 new cases and more than 125,000 deaths annually. In Japan, Yuya Yokochi et al., 2025 reported that NSCLC accounts for nearly 90% of lung cancer cases. In Spain, Mariano Provencio et al., 2025 documented 13,583 patients with stage IV NSCLC within a registry cohort, highlighting the substantial metastatic disease burden across European populations. Similar rising incidence trends are also observed across the United Kingdom, Germany, France, Italy, and India.

Metastatic Non-small Cell Lung Cancer: Treatment Overview

Treatment for metastatic non-small cell lung cancer focuses on controlling disease progression, relieving symptoms, and improving survival outcomes. Therapeutic strategies are guided by tumor histology, molecular biomarkers, and patient health status. Common approaches include systemic therapies such as chemotherapy, targeted therapy directed at specific genetic alterations (for example EGFR, ALK, or ROS1 mutations), and immune checkpoint inhibitors that enhance antitumor immune responses. Radiation therapy may be used for symptom control or management of metastatic lesions. In selected cases, combination regimens integrating immunotherapy and chemotherapy are employed to achieve improved clinical outcomes.

Key Questions Answered

• What are the key findings of metastatic non-small cell lung cancer epidemiology in the 8 major markets?
• What will be the total number of patients with metastatic non-small cell lung cancer across the 8 major markets during the forecast period?
• What was the country-wise metastatic non-small cell lung cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of metastatic non-small cell lung cancer patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of metastatic non-small cell lung cancer during the forecast period of 2026-2035?
• What are the currently available treatments for metastatic non-small cell lung cancer?
• What are the disease risks, signs, symptoms, and unmet needs of metastatic non-small cell lung cancer?

Scope of the Metastatic Non-small Cell Lung Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of metastatic non-small cell lung cancer based on several factors.
• Metastatic Non-small Cell Lung Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The metastatic non-small cell lung cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.